Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 billion) in total sales in 2021 and is expected to grow 1.1% One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. in 2022 to JPY9.498 trillion ($68.08

Drug Pricing 69

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 69

Pharmaceutical Technology

NOVEMBER 21, 2022

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 billion) in total sales in 2021 and is expected to grow 1.1% One reason at play is the concern that the Japanese pharmaceutical industry has shown about the impact of annual price revisions. in 2022 to JPY9.498 trillion ($68.08

Drug Pricing 52

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing 52

European Pharmaceutical Review

DECEMBER 21, 2022

2 However, most of these efforts relating to catalysis, 3 process waste metrics, 4 lifecycle assessments, 5 pharmaceuticals in the environment 6 and the phase out of substances of concern 7 mainly mitigate the consequences of pharmaceutical manufacturing. Defossilization of pharmaceutical manufacturing.

Compounding 97

Compounding Pharmaceutical Manufacturing Pharmaceutical Companies Pharmaceutical Companies 97

Pharmaceutical Technology

FEBRUARY 3, 2023

In 2021, 72% of newly approved drugs were small molecules, and almost 50% of new drugs approved were OSD. Tablet manufacturing, which is the most common OSD form, takes an API dry powder ingredient and compresses it to form tablets, which can be coated or uncoated.

Dosage 52

Dosage Pharmaceutical Manufacturing Packaging Communication 52

GMPSOP

JUNE 28, 2024

Adulterated Pharmaceuticals: 396 warnings iii. Packaging/labeling/Misbranding: 41 warnings vi. Failure to comply with regulations was the biggest (30%) reason for warning letters in 2021. Similarly, the packaging, labeling, and misbranding-related warning letters were the top reasons in 2019.

Documentation 59

Documentation Packaging Labelling Pharmaceutical Manufacturing 59

European Pharmaceutical Review

AUGUST 10, 2023

Amidst numerous warning letters distributed by the US Food and Drug Administration (FDA) to pharmaceutical manufacturers in recent months, in July this year, the US regulatory body published its analysis on drug product quality in 2022. The FDA acknowledged that while Edge Biologicals Inc.’s

Pharmaceutical Manufacturing 98

Pharmaceutical Manufacturing Packaging 98

European Pharmaceutical Review

OCTOBER 17, 2022

Sanofi has signed definitive agreements with Adragos Pharmaceutical, a German contract development and manufacturing organisation (CDMO), for the sale of its pharmaceutical manufacturing site in Kawagoe, Japan. The French pharmaceutical company will also enter into a long-term supply agreement with the CDMO.

Pharmaceutical Manufacturing 104

Pharmaceutical Manufacturing Packaging Diabetes Pharmaceutical Companies 104

Pharmaceutical Technology

MARCH 22, 2023

To keep the EU’s medicine supply intact, Gupta suggests governments should adopt new pricing policies and provide further aid to mitigate the impact of rising operational costs; they should also minimise the exodus of generics manufacturers. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

Pharmaceutical Manufacturing 105

Pharmaceutical Manufacturing Packaging Communication Diabetes 105

Viseven

SEPTEMBER 14, 2023

For example, a pharmaceutical brand can face increased acquisition costs if a supplier has not delivered on time. It also bears extra replacement expenses when drugs are discarded due to improper packaging. Technologies allow pharmaceutical companies to collect and analyze a massive amount of data to ensure proper drug safety.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies Dosage 52

Quality Matters

OCTOBER 13, 2021

In addition to standards for active pharmaceutical ingredients, USP also develops standards for the inactive ingredients (excipients) and other raw materials used in drug manufacturing. In a 2019 report on drug shortages, the FDA found that 62% of drug shortages occur because of quality issues in manufacturing.

Pharmaceutical Manufacturing 52

Pharmaceutical Manufacturing Adverse Reactions Prescription Filling Compounding 52

Pharmaceutical Technology

AUGUST 30, 2022

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.

Vaccines 78

Vaccines Pharmaceutical Manufacturing Packaging 78